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Abstract 
 
Endoscopic Submucosal Dissection (ESD) has gained worldwide acceptance as a treatment for Early 
Gastrointestinal Cancers (EGICs). However, the management of these tumors in the Western world is 
still mainly surgical. 
Our aim was to evaluate the safety and feasibility of ESD in a European center. 
Based on the knowledge transferred by one of the most experienced Japanese Institutions, we 
conducted a pilot study on 25 consecutive patients with EGICs located in the esophagus (n=3), 
stomach (n=7), duodenum (n=1) and colon (n=14) at our tertiary center over a 2-year-period. Main 
outcome measurements were complete (R0), as were en bloc resection and management of 
complications. 
R0 and en bloc resection rates were 100% and 84% respectively. There were 3 bleeding and 5 
perforation cases. With a median follow-up of 15 months, 2 recurrences were observed. 
ESD for early esophageal and gastric cancers is feasible and effective while colonic ESD requires 
more expertise. 
 
 
Key words: Gastrointestinal Neoplasms; Endoscopic Submucosal Dissection; Endoscopic 
Gastrointestinal Surgery. 
 
 
 
 
 
 
 
 
3 
 
Introduction 
 
In the era of minimal invasive therapy, ESD has gained wide acceptance in Asian countries for the 
treatment of EGICs [1-3].  
In the West, ESD is rarely reported [4-8], both because of the apparent lower incidence of EGICs and 
of the much rarer usage of this technique.   
We report a single center exploratory programme involving 25 cases of ESD for treatment of EGICs, 
performed at “Paride Stefanini” Surgical Department, University of Rome “La Sapienza”, Italy. 
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Case Reports 
 
Twenty-five unselected consecutive patients (10 M, 15 F; mean age 70 years, range 47-88 years) with 
EGICs underwent ESD at our Institution from April 2007 to September 2009. 
There were 3 esophageal, 7 gastric, 1 duodenal and 14 colonic lesions (Table 1). The mean size of the 
lesions was 25 mm (range 10-50 mm). 
Inclusion criteria followed those of Oyama [9] for lesions of the esophagus; the extended Gotoda 
criteria for the stomach [10]; and Laterally Spreading Tumors (LSTs) greater than 20 mm in diameter 
[11] or Paris 0-II type lesions for the colon. 
 
Preoperative Evaluation 
The diagnostic endoscopy included contrast chromoscopy with 0.2% indigo carmine dye or 2.5% 
Lugol solutions, or Narrow Band Imaging (NBI) inspection, together with Magnifying Endoscopy 
(110 to 150x, Olympus GIFQ160Z or CFQ160Z). Histological assessment confirmed the lesions as 
Low Grade or High Grade Non Invasive Neoplasia (LGNIN or HGNIN). 
All the patients were informed by oral and written explanation about the planned treatment. They were 
aware of the level of experience in ESD of the two operators (SC, PT). This study was conducted in 
accordance with the ethical principles of the Declaration of Helsinki and without any external financial 
support. 
 
ESD technique 
It-knife, Hook-knife or Dual-knife (Olympus Medical Systems Corp., Tokyo, Japan) were used for 
dissection (Olympus PSD-60, Endocut Mode, Effect 3, 60 to 80 Watt Cutting, 20 Watt Forced 
Coagulation), after multiple injections with saline and epinephrine solution (1:20000), stained with 
indigo-carmine, and further repeated injections of hyaluronic acid or 10% glycerol. An attachment cap 
was regularly used in order to facilitate the dissection.  
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In cases of failed en bloc removal, final excision was achieved using a polypectomy snare in a 
piecemeal fashion. 
At the end, careful inspection of the ulcer site and coagulation of borders and visible vessels was 
routinely performed. 
 
Outcomes and management 
The main outcomes of the study were the feasibility of ESD, data on the percentage of en bloc and 
complete resection, and an indication of various possible complications. 
Feasibility was indicated by the number of ESDs successfully accomplished.  
All the patients were operated on in the operating theatre, under propofol sedation, with a surgical 
team available to treat possible complications not manageable endoscopically. 
The following day, patients had plain abdominal x-rays to rule out perforation, and in the absence of 
bleeding signs, they were allowed a liquid diet 24-48 hours after the procedure. Proton pump 
inhibitors were routinely administered for 1 month in gastric-lesion patients only.  
 
Follow-up 
Follow-up (FU) with biopsies included a 1, 3 and 12-months examination. 
Recurrence was defined as the presence of pathological tissue at the resection site. 
 
Complications 
Minor bleeding was immediately treated with repeated injections of saline solution or with the 
Coagrasper forceps (Olympus Medical Systems Corp., Tokyo, Japan). 
Perforation was defined as the endoscopic intraoperative diagnosis of a hole in the viscus, or the 
presence of free air the following day on plain x-ray, with or without clinical signs. All identified 
perforations were treated intraoperatively by clips apposition (Resolution Clip, Boston Scientific, 
Natick, MA, USA). 
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Histopathologic assessment 
The specimens were fixed and orientated on a board. After fixation, the samples were sectioned at 2-
mm intervals parallel to the closest resection margin to assess both lateral and vertical margins. 
Multiple histological sections (at least 10) were obtained from each paraffin block, stained with 
Hematoxylin-eosin. 
 
Results 
En bloc resection was feasible in 3/3 esophageal, 6/7 gastric, 1/1 duodenal and 10/14 colonic cases 
(overall 84%). Complete resection was achieved in all the en bloc procedures. Median operating time 
was 120 minutes (range 30-360 minutes). The median follow-up was 18 months (range 3-33 months). 
Comparing to preoperative diagnosis, histological examination of the whole sample resulted in 6 up-
stagings and 1 down-staging. 
Overall, bleeding accounted for 12% and perforation for 20% of cases. 
In one case occurred an esophageal substenosis. 
Disease recurrence was present in 2 cases. 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Discussion 
 
Japanese experts recommend performing ESD on gastric lesions first, as they are technically easier to 
remove and exhibit a lower rate of complications compared to esophageal or colonic lesions [10, 12-
14]. 
Nevertheless, it was decided to include all consecutive unselected cases referred to our Department. 
This was a research programme aimed at assessing the feasibility of ESD as an alternative treatment 
for EGICs in a University Hospital with an estimated catchment area of about 1.000.000 inhabitants.  
SC attended the NCCH in Tokyo for 3 months, to gain practice before the first autonomous procedure. 
For the first month of his training, he observed at least 3-5 complete procedures per day performed by 
TG and his team. He then started to practise on isolated pig stomachs, performing about 3 ESDs per 
week. In the third month, he performed under the strict supervision of TG 3 ESDs in 3 patients with 
EGC. Throughout this period, he followed the team in all their clinical duties, including the 
management of complications. 
PT has 26 years of experience in therapeutic and emergency endoscopy. He observed at least 30 
videos of ESD performed by TG and his colleagues. 
The first 3 procedures were performed by SC supervised by TG. Then, SC performed autonomously 
14 procedures and assisted PT in performing 2 cases. The last 6 ESDs were performed by PT 
autonomously. 
EGC is the most accepted indication for ESD worldwide. In Western countries, only a few series have 
been recently published with encouraging results [15-17]. 
Overall, we had a satisfactory en bloc and complete resection rate for upper GI cancers (90%), while it 
was lower for colonic series (72%). 
In the literature, the perforation rate ranges between 1-10% [11, 18-21].  
There was a high perforation rate in our small colonic series, probably because of the initial 
experience with ESD and the unselected cases. However, all of them were recognized at the time of 
operation, and subsequently clipped. Only 1 case received a EUS-guided needle decompression. 
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Only in 1 gastric case, surgery was required. It was the case of an 83-year-old patient with a large 
EGC (40 mm) at the beginning of our study. Twenty-four hours after the procedure, a small amount of 
free air was seen at the plain x-ray, but an emergency laparotomy failed to disclose evidence of 
perforation. The patient died 40 days later of respiratory insufficiency, presumably as a consequence 
of laparotomy. 
Substenosis occurred after one esophageal ESD. It was a case of HGNIN within an 8 cm long segment 
of circumferential Barrett’s esophagus and was effectively managed by endoscopic balloon dilation. 
Recurrence was present in 1 giant (50 mm) recurrent antral hyperplastic polyp, responsible for severe 
anemia. Suspecting neoplastic progression, we performed an en bloc and complete ESD (Figure 3). At 
the 3-months-FU endoscopy again a 10 mm recurrence was noted. EUS was then performed without 
any clear explanation for this recurrence. This patient was retreated by a standard polypectomy and 
Argon Plasma Coagulation. 
One gastric case was a solitary antral nodule, which was a recurrent localized mantle cell Lymphoma 
This patient, who had received chemotherapy (CHT) and bone marrow transplantation, was offered an 
ESD as alternative treatment to further CHT (Figure 4). She is disease free at the 6-month endoscopic 
control. 
 
Conclusions 
Our study has many limitations: a limited and heterogeneous cohort, with and without prior 
endoscopic treatment, with and without neoplasia; 2 operators with a variable experience and learning 
curve; limited FU for several cases. However, we have demonstrated a successful cooperation and 
transfer of practical knowledge between 2 tertiary Institutions with hitherto differing therapeutic 
approaches. 
Following this preliminary experience, ESD has been introduced in our hospital clinical practice as an 
experimental alternative treatment to surgery for early GI cancers.  
In summary, we believe that: 
- At least 30 procedures should be carefully observed for each location. 
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- At least 10 ESD should be performed on animal models before starting with patients (stomach 
only), and at least 3 initial procedures should be supervised by foreign experts; 
- Colonic ESD should be performed in the lower rectum first; the right colon should be 
attempted only after adequate experience. 
- Initial experiences should be performed in specialized centers. Caution is mandatory, and tight 
cooperation with a surgical team is advisable. 
ESD for early esophageal and gastric cancers is feasible and effective.  
Colonic ESD requires considerably more training due to the high risk of perforation and more 
cooperation with our expert Asian colleagues is needed to achieve the expertise appropriate for facing 
difficult lesions.  
A more extended study is necessary to confirm the results of the small scale study presented here and 
more studies in the West are needed to identify full guidelines for the use of this technique. 
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Figure legends 
 
Figure 1 
A: Early gastric cancer (0-IIa+IIc type, 15 mm), of the fundus, along the lesser curvature just below 
the cardia, after staining with indigo-carmine. 
B: Residual ulcer after endoscopic submucosal dissection. 
C: En bloc excised lesion fixed orientated on a board for the histopathologic assessment. 
D: Well differentiated (G1) intramucosal ADC of intestinal type, vertical margins free of tumor 
(hematoxylin-eosin, original magnification 20X). 
 
Figure 2 
A: Laterally Spreading Tumor (non-granular type, 40 mm) of the sigmoid colon. 
B: Dissection of the submucosal layer by It-knife. 
C: En bloc excised lesion fixed orientated on a board for the histopathologic assessment. 
D: Well differentiated (G1) adenocarcinoma. The lesion is largely intramucosal, with focal infiltration 
of the muscularis mucosae (hematoxilin-eosin, original magnification 10X). 
 
Figure 3  
A: Giant recurrent hyperplastic polyp of the gastric antrum, 50 mm, after staining with indigo-
carmine. 
B: Circumferential incision performed by Hook-knife around the polyp, outside the marking dots. 
 
Figure 4 
A: Solitary gastric nodule of recurrent localized mantle cell Lymphoma. 
B: Submucosal dissection performed by It-knife. 
C: En bloc excised lesion fixed orientated on a board for the histopathologic assessment (mucosal 
side). 
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D: En bloc excised lesion fixed orientated on a board for the histopathologic assessment (submucosal 
side). 
 
 
Table 1. Description of cases 
Patient Lesion Procedure Outcomes 
Case (no) Age (y) Sex Type Major diameter (mm) Histology Location Time (min) Resection Complications Management Histopathologic result Follow up (mo) Recurrence 
1 70 M 0-IIb 20 HGNIN Body 60 R0 En bloc   HGNIN 33  
2 65 F 0-IIb 20 HGNIN Body 50 R0 En bloc   HGNIN 33  
3 67 M 0-IIa 25 HGNIN Antrum 90 R0 En bloc   HGNIN 33  
4 83 M 0-IIa+IIb 40 HGNIN Antrum 360 R0 Piecemeal (snare) Perforation op. surgery pTis G1 †  
5 74 F G-LST 40 HGNIN Left colon 120 R0 Piecemeal (snare) perforation, delayed bleeding clipping, conservative HGNIN 27 Yes 
6 70 F G-LST 40 HGNIN Sigmoid colon 180 R0 Piecemeal (snare)   HGNIN 24  
7 64 F 0-IIa 15 HGNIN Cecal fundus 30 R0 En bloc + lap. appendectomy perforation clipping, lap. surgery HGNIN 23  
8 63 M 0-IIa+scar 10 HGNIN Rectum 60 R0 En bloc   HGNIN 21  
9 79 M 0-IIa+IIc 15 HGNIN Fundus 90 R0 En bloc immediate bleeding It-knife, Coagrasper pT1 G1 21  
10 72 M NG-LST 20 LGNIN Transverse colon 50 R0 En bloc   LGNIN 21  
11 80 F NG-LST 20 LGNIN Cecum 180 R0 piecemeal (It-knife)   LGNIN 18  
12 81 F Ip 50 Hyperplasia Antrum 150 R0 En bloc immediate bleeding It-knife, Coagrasper Hyperplasia 18 Yes 
13 76 F NG-LST 40 HGNIN Sigmoid colon 240 R0 En bloc   pTis G1 14  
14 88 F 0-I 20 HGNIN Esophagus 240 R0 En bloc   pT1 G2 14  
15 47 F G-LST 20 LGNIN Right colon 180 R0 En bloc perforation clipping, decompressive puncture LGNIN 13  
16 66 M 0-IIc 20 HGNIN Esophagus 120 R0 En bloc   LGNIN 12  
17 61 F 0-I 15 Mantle Cell Lymphoma Antrum 60 R0 En bloc   Mantle Cell Lymphoma 11  
18 58 F NG-LST 30 LGNIN Sigmoid colon 150 R0 En bloc   LGNIN 9  
19 69 M G-LST 40 LGNIN Rectum 240 R0 En bloc   LGNIN 8  
20 64 F 0-IIa 12 HGNIN Esophagus 90 R0 En bloc substenosis balloon dilation HGNIN 7  
21 66 F 0-IIa 12 LGNIN Duodenum 90 R0 En bloc   LGNIN 6  
22 81 F G-LST 30 LGNIN Right colon 110 R0 En bloc   HGNIN 4  
23 57 M G-LST 25 LGNIN Right colon 240 R0 En bloc   LGNIN 3  
24 62 M G-LST 25 LGNIN Right colon 180 R0 En bloc perforation clipping HGNIN 3  
25 74 M G-LST 20 LGNIN Rectum 120 R0 En bloc   LGNIN 3  
 
HGNIN, High Grade Non Invasive Neoplasia; LGNIN, Low Grade Non Invasive Neoplasia; G-LST, Granular type Laterally Spreading Tumor; 
NG-LST, Non Granular type Laterally Spreading Tumor. 
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Mini Abstract 
Based on the know-how transfer by a Japanese Institution to a European center, encouraging results 
are coming from a pilot study of 25 patients with EGICs treated with ESD. 
 
*Mini-abstract (less than 30 words)
